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SUMMARY 
Objectives: This study investigated the immunologic 
responses and employment history of highly-active 
antiretroviral therapy (HAART) patients. 
Design: We interviewed patients and reviewed medical 
records to collect demographic, clinical, and employ-
ment history while on HAART. Demographic charac-
teristics were tested as predictors of immunological 
response while on HAART using hierarchical linear 
models.  
Setting: Fevers Unit, Korle-Bu Teaching Hospital, 
Accra, Ghana 
Participants: Subjects comprised a convenience sam-
ple of adult HAART patients receiving therapy for at 
least 9 months. 270 patients were interviewed. 38 were 
excluded due to inadequate time on HAART or inabil-
ity to locate all necessary patient information.  
Intervention: This was an observational study.  
Main outcome measures: We investigated the change 
in CD4 cell count and weight since the initiation of 
therapy, and their ability to maintain or regain em-
ployment as well as the reasons for this.  
Results: The estimated mean ± standard error increase 
in CD4 cell count from baseline at 6, 12, and 18 
months were 102 ± 5, 204 ± 11, and 236 ± 10 cells/µL, 
respectively. Overall, 147 patients (63.4%) reported 
remaining employed or obtaining new employment 
while on HAART. Patients who were asymptomatic at 
initial presentation were more likely to remain em-
ployed or returned to work while on HAART than 
those who were symptomatic (66.4% vs. 48.8%, P = 
0.009). Most patients were employed in the informal 
sector, which made their economic situation particu-
larly vulnerable to HIV-associated illness. 
Conclusion: The findings suggest that patients receiv-
ing HAART experience good clinical and immunologi-
cal responses as well as improvement in employment 
status. 
 
Keywords: Highly active antiretroviral therapy, em-
ployment, HIV, socioeconomic factors, Ghana 
 
INTRODUCTION 
The human immunodeficiency virus (HIV) epidemic 
continues to be a major public health problem, particu-
larly in sub-Saharan Africa where 67% of infected 
people live and where 75% of AIDS deaths occurred in 
2007.
1
 HIV disease presents both social and economic 
challenges for patients, families, and employers. HIV-
related stigma, disability, and death can have profound 
effects on household income,
2-5
 making patients unable 
to work or forcing them to work less. Sub-Saharan Af-
rica has long been plagued by underdevelopment; the 
negative effects of HIV illness thus often occur in a 




Several studies have demonstrated significant immu-
nologic recover and suppression of viral replication 
with highly active antiretroviral therapy (HAART).
7-10
 
Highly active antiretroviral therapy (HAART) has been 
associated with increased probability of remaining em-
ployed for people living with HIV/AIDS (PLWHA) in 
industrialized countries,
11, 12
 and a prospective study in 
India also found a significant increase in employment 




However, little information exists in the English lan-
guage literature about the interplay of HAART and 
employment in sub-Saharan Africa. Studies from other 
settings cannot be extrapolated to African settings be-
cause of regional and social differences in the demo-
graphics of AIDS. We hypothesized that improvement 
in physical well being due to HAART would allow 
HIV-infected persons to obtain and/or remain in em-
ployment. In Ghana, antiretroviral therapy is provided 
through a government-sponsored program.  Patients 
pay a subsidized monthly fee of 5 Ghana Cedis for 
counselling, doctor’s visit and antiretroviral medica-
tion.  
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HAART is initiated for HIV patients if they have 
AIDS-related symptoms, CD4+ counts < 250 
cells/mm
3
, or opportunistic infections according to 
WHO treatment guidelines. Patients are seen at least 
every 4 months for clinical assessment, adherence 
monitoring, CD4 count measurements, and counselling 
when necessary.  
 
HIV viral loads are not performed as a part of routine 
care. As of August 2007, over 9100 patients had been 
enrolled in the treatment program. In this study, we 
characterized the clinical response to HAART and in-
vestigated the factors associated with employment for 
patients who had received at least nine months of ther-




Clinical changes and employment status were investi-
gated in patients on HAART by performing a cross-
sectional survey and retrospective review of medical 
records of HIV-infected patients receiving HAART at 
the Fevers Unit, Korle-Bu Teaching Hospital in Accra, 
Ghana, as part of the national AIDS treatment program. 
The study was reviewed and approved by the Institu-
tional Review Boards of the University of Ghana 
Medical School, Accra and Brown University, Provi-
dence, Rhode Island. Written consent was obtained 
from each patient prior to commencement of the inter-
view. 
 
Study patients and study procedures 
A questionnaire with both open- and closed-ended 
questions was developed to assess patients’ social and 
demographic characteristics, disclosure of status, and 
employment history. It was piloted in focus groups 
comprised of nurses and clerical workers at Korle-Bu 
Teaching Hospital to improve its contextual appropri-
ateness. 
 
The study was conducted during a seven-week period 
from June until August July of 2007. Several hundred 
patients attend each thrice-weekly clinic; patient selec-
tion was performed by clinic staff who were asked to 
choose eligible patients at random from those attending 
that day’s clinic for follow-up routine HIV care. Eligi-
bility criteria were that patients were at least 18 years 
old and had been on HAART for at least 12 months. A 
single interviewer performed all interviews.  
 
They were conducted in English with subjects who 
were fluent in English or, more frequently, in Twi or 
Ewe using bilingual clinic staff as translators.  The 
questionnaire took approximately 12 minutes to com-
plete. A total of 270 patients were interviewed accord-
ing to this protocol. Following the interviews, subjects’ 
medical records were reviewed for demographic, clini-
cal, and laboratory data, including World Health Or-
ganization (WHO) clinical stage.
14
 Of the patients who 
had completed the interview, those whose medical re-




Analyses were performed using SAS version 9.1.3 
(Cary, NC).  Each demographic and clinical feature 
was tested as a predictor of immunological response 
while on HAART, as demonstrated by changes in CD4 
counts. The number and timing of CD4 counts was 
variable between patients, as well as the length of fol-
low-up and overall CD4 level.  Therefore, hierarchical 
modeling was used to model these changes, allowing 
each patient to have their own best-fit function over 
time at the 1
st
 level, and the aggregated function across 
patients at the 2
nd
 level for testing hypotheses.  This 
method both allows for variable times of measurement 
and would produce unbiased estimates when missing 
data was missing at random. Different slopes were 
modelled in the first year than in subsequent years to 
allow for patients’ expected decreasing response to 
HAART.  This model included both fixed and random 
intercepts, slopes, and changes in slope at 12 months, 
with an unstructured variance-covariance structure for 
the random effect parameters. Follow-up models were 
used to test whether or not baseline factors moderated 
the 1
st
 year and subsequent slopes by including interac-
tions of the baseline factor with the slope and change in 
slope after 1 year.  The factors themselves were also 
included as fixed effects in these models, permitting 
testing and adjusting for disparate starting points. 
 
 Demographic and clinical features were tested for dif-
ferences by employment status using chi-square or 
Fisher’s exact tests for categorical variables and Stu-
dent’s t-tests for continuous variables. All statistical 





Of the 270 subjects who were interviewed, 232 (86%) 
were included in the final analyses. The difference con-
sisted mostly of patients whose medical charts could 
not be found at the clinic following their medical ap-
pointments. Additionally, chart review revealed a 
handful of patients to have been on HAART for less 
than 12 months. Patients who had received at least 9 
months of treatment were included in the analyses.  
The baseline demographic characteristics of the study 
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 Table 1 Baseline characteristics of the study subjects 
Variable Number % 
Age (Years) (n=231)   
Mean (SD) 39.0 (9.0) 
Range 19 – 67   
Age distribution (n=231)   
19 – 29  48 20.8 
30 – 39 77 33.3 
40 – 49  74 32.0 
≥ 50 32 13.9 
Female gender 162 70.0 
Marital status   
Married  103 44.4 
Single 53 22.8 
Widowed 38 16.4 
Divorced 27 11.6 
Separated 8 3.4 
Cohabiting 2 0.9 
Unknown 1 0.4 
Education   
University 13 5.6 
Secondary/Technical 51 22.0 
Junior secondary 116 50.0 
Primary 22 9.5 
None 23 9.9 
Unknown 7 3.0 
Source of emotional support 
(n=117) 
  
Family 110 94 
Friends 6 5.0 
Other 1 1.0 
WHO staging (n=207)   
1 12 5.8 
2 70 33.8 
3 104 50.2 
4 21 10.1 
Baseline CD4 cell count 
(cells/µL) 
  
Mean (SD) 126.9  (89.3) 
Range 1 – 407   
Antiretroviral regimen   
ZDV/3TC/EFV 85 36.6 
ZDV/3TC/NVP 75 32.3 
D4T/3TC/EFV 34 14.7 
D4T/3TC/NVP 34 14.7 
ZDV/3TC/NFV 2 0.9 
D4T/ABC/EFV 1 0.4 
Unknown 1 0.4 
SD, standard deviation; WHO, World Health Organization; 
ZDV, zidovudine; 3TC, lamivudine; EFV, efavirenz; NVP, 
nevirapine; D4T, stavudine; NFV, nelfinavir; ABC, abacavir. 
 
The mean (± SD) age was 39  9 years, 70% were fe-
male, and 44.4% were married. Patients had been on 
HAART for a mean (± SD) duration of 27 (± 9.7) 
months. The most commonly prescribed medication 
regimens were lamivudine/zidovudine plus nevirapine 
(36.6%) and lamivudine/zidovudine plus efavirenz 
(32.3%).  
 
Clinical and immunological response to HAART 
The mean (± SD) baseline CD4 cell count prior to ini-
tiating HAART was 127  89 cells/µl, and 60.3% of 
patients had WHO stage 3 or 4 disease. There was wide 
variability in baseline levels and changes in CD4 cell 
count, hemoglobin values, and body weight over time.   
 
Overall, the estimated mean (± standard error (SE)) 
increases in CD4 cell count from baseline at 6, 12 and 
18 months were 102 ± 5, 204 ± 11, and 236 ± 10 
cells/µL, respectively.  The estimated mean (± SE) 
increases in hemoglobin at 6, 12, and 18 months were 
1.0 ± 0.2, 2.1 ± 0.3, and 2.2 ± 0.3 g/dL, respectively.  
The estimated mean (± SE) increases in body weight at 
6, 12, and 18 months were 3.9 ± 0.3, 7.9 ± 0.6, and 7.6 
± 0.6 kilograms, respectively.  
 
 The observed mean increases in CD4 cell count, he-
moglobin, and body weight in the first year were all 
statistically significant (P < 0.0001), whereas only CD4 
cell count continued to increase after the 1
st
 year (p 
<0.0001). We also evaluated factors associated with 
early (within 1 year) and late CD4 cell count and 
weight changes while on HAART.   
 
Overall, the mean (± SE) increase in CD4 cell count 
was 17.1 ± 0.9 cells/µL per month in the first year of 
HAART and 5.3 ± 0.8 cells/µL per month after the first 
year.  Gender was the only factor that was associated 
with CD4 count change in the first year of HAART. 
The estimated mean (± SE) increase in CD4 cell count 
was 18.2 ± 1.6 cells/µL among females compared with 
14.2 ± 1.0 cells/µL in males in the first year of HAART 
(P = 0.035).  The change in CD4 cell count over time 
was not influenced by other measured factors (Table 
2).   
 
The most commonly held occupations at the time of 
interview were trader or food vendor (41.8%), labourer 
(15.1%), seamstress (10.8%), and hairdresser (7.3%).  
Of the 212 patients who had ever worked, 70.3% were 
self-employed.  Of the 226 patients who were working 
before becoming symptomatic with HIV, 75.7% re-
ported taking leave from work or losing their job.  At 
the time of their interviews, 147 (63.4%) of the 232 
patients reported that they were working.  Of the 171 
patients who took leave from work or lost their job 
after becoming symptomatic, 101 (59%) resumed work 
or obtained new employment. Reasons for temporary 
or permanent loss of employment included physical 
inability, loss of business capital, and being fired.  
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Overall, of the 75 patients who started new employ-
ment on HAART, 47 (62.7%) earned less money than 
before their illness. Patients who were asymptomatic at 
the time of HIV diagnosis were more likely to be work-
ing than symptomatic patients (66.4% versus 48.8%, p 
= 0.009).  Other measured factors such as age, gender, 
marital status, educational status, baseline CD4 cell 
count and WHO disease stage were not associated with 
employment status while on HAART (data not shown 
in tables). 
  
Table 2 Mean (standard error ) rate of CD4 cell count (cells/l) increase per month in the first year and after one 
year of antiretroviral therapy, by patient factors. 
  Up to 1 year After 1 year 
 Variable  Change 
in CD4 
P value Change 
in CD4 
P value 
Gender Male 14.2 (1.0) 0.04 4.9 (1.4) 0.24 
  Female 18.2 (1.6)  5.5 (1.0)  
Marital status Single 18.4 (1.2) 0.10 4.9 (1.1) 0.19 
  Married 15.4 (1.3)  5.6 (1.3)  
Education None/primary 15.4 (2.0) 0.33 7.3 (2.0) 0.21 
  > primary 17.6 (1.0)  4.9 (0.9)  
Alcohol use Yes 15.7 (2.3) 0.72 4.2 (2.3) 0.85 
 No 16.5 (0.9)  5.8 (0.9)  
Currently working Yes 17.5 (1.1) 0.49 5.4 (1.0) 0.82 
  No 16.3 (1.5)  4.8 (1.4)  
Lost job/took leave  Yes 17.1 (1.0) 0.89 4.5 (1.0) 0.47 
  No 17.3 (1.8)  7.1 (1.6)  
Disclosure to family Yes 17.4 (1.5) 0.76 5.2 (1.4) 0.80 
 No 16.8 (1.1)  5.3 (1.0)  
Disclosure to 
spouse/partner 
Yes 17.4 (1.1) 0.56 4.1 (1.1) 0.20 
  No 16.4 (1.4)  6.7 (1.3)  
Disclosure to friend/pastor Yes 17.2 (1.0) 0.77 5.2 (1.0) 0.75 
 No 16.5 (2.0)  5.6 (1.8)  
Disclosure to parent Yes 16.3 (1.1) 0.25 5.3 (1.1) 0.43 
  No 18.5 (1.3)  5.2 (1.4)  
Disclosure to employer Yes 17.2 (0.9) 0.34 5.3 (0.9) 0.55 
 No 12.9 (4.4)  5.3 (4.4)  
 
The mean change in body weight was not influenced 
by any measured patient factors (data not shown) 
 
Employment and factors influencing employment 
while on HAART 
The cross-sectional patient interview responses are 
summarized in Table 3. 
 
DISCUSSION 
In this study, we surveyed surviving HIV/AIDS pa-
tients attending a large urban clinic in Ghana about 
their employment experiences before and during ther-
apy. A high proportion of patients recalled having lost 
their employment, at least temporarily, after becoming 
symptomatic.  However, the majority of these patients 
were able to resume work or obtain new employment 
after initiating HAART.  
 
 
While not conclusive owing to a lack of a control sam-
ple, our findings suggest that HAART may improve 
employment status, as would be consistent with find-




There were significant increases in CD4 cell counts, 
haemoglobin, and body weight while patients were on 
HAART.  The mean increases in CD4 cell counts and 
body weight were independent of any factors that we 
measured except gender, where women had a higher 
rate of increase in CD4 cell count in the first year of 
therapy. The importance of this difference is not clear 
from our analysis. The observed increase in CD4 cell 
count paralleled what other researchers have found in 
West Africa,
10
 and demonstrates the effectiveness of 
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The only factor that was associated with a higher prob-
ability of continuing or obtaining new employment 
during therapy was being asymptomatic at the initiation 
of HAART.  This corroborates similar findings in in-
dustrialized countries,
15, 16
 and underscores the impor-
tance of early HIV diagnosis and treatment. 
 
A majority of the patients in this study worked in the 
informal sector as petty traders, seamstresses, hair-
dressers, and manual labourers. Individuals employed 
in the informal sector generally have no savings or 
insurance, and thus are particularly vulnerable to eco-
nomic and personal stresses. 
 
Table 3 Interview responses regarding socioeconomics 
characteristics for 232 HIV-infected patients who had 
received at least nine months of antiretroviral therapy 
Variable  Number % 
Duration of ART at the time of in-
terview (months) 
  
Mean (SD) 27 (9.7)  
Range 9.2 – 
44.1 
 
Occupation   
Trader or food seller 97 41.8 
Labourer 35 15.1 
Seamstress 25 10.8 
Hairdresser 17 7.3 
Driver 10 4.3 
Teacher 6 2.6 
Clerical 6 2.6 
Management 6 2.6 
Other 17 7.3 
Unemployed 13 5.6 
Self-employed (n=212) 149 70.3 
Currently Working 147 63.4 
Same occupation (n=147) 91 61.9 
Lost job or took leave since diagno-
sis (n=226) 
171 75.7 
Reason for leave/job loss (n=168)   
Physical inability 108 64.3 
Lost of capital 27 16.1 
Fired  18 10.7 
Lost customers 6 3.6 
Resigned 5 3.0 
Family leave 4 2.4 
Started new job since illness 
(n=122) 
79 64.8 
Started new job after ART (n=78) 55 70.5 
Making less money with new job 
(n=75) 
47 62.7 
ART, antiretroviral therapy; SD, standard deviation, n, num-
ber of patients. 
  
 
Physical disability due to HIV-related illness reduces 
patients’ income and presents additional costs includ-
ing medical care, funerals, and the care of orphaned 
children.
2-6, 17-19
 HIV infection is particularly disastrous 
for patients with pre-existing poverty and poor health, 
an effect that is not entirely negated by HAART. Early 
diagnosis through routine testing and early initiation of 
HAART may prevent many of the deleterious eco-
nomic effects of HIV-related illness. Vocational reha-
bilitation and access to micro credit may mitigate the 
impact of AIDS on self-employed patients. 
  
There are several potential limitations to our methods 
that merit discussion. There were several possible 
sources of sampling bias. Clinic staff were asked to 
identify eligible subjects ‘at random,’ but no formal 
process ensured the randomness of the sample. Patients 
who were lost to follow up due to death, deteriorating 
health, lack of money, or other reasons were not repre-
sented in the study. The results may therefore reflect an 
overly optimistic view of patients on HAART. 
 
Additionally, an in-house questionnaire was developed 
and used which was not formally validated or checked 
for reliability. Despite piloting, some questions did not 
seem to make sense in the cultural context of Ghanaian 
society. The definition of occupation may also be prob-
lematic. Other researchers, working in Ghana, have 
noted that people engaged in informal enterprises may 
have several income generating activities at any given 
time, picking up and dropping them as their situations 
change.
20,21
 The questionnaire asked patients about 
changes in their occupation, attempting to gauge how 
HIV-related illness and HAART affect employment 
and personal financial stability. However, it may have 
inadequately assessed part-time informal ventures that 
may have contributed to patients’ income. Although 
the study did not adequately anticipate patients’ eco-
nomic situations, the interviews elucidated the eco-
nomic fragility of patients employed in the informal 
sector. 
 
The data show that, on average, patients receiving 
HAART increased in CD4 cell count, hemoglobin, and 
weight. The majority of those patients who had lost 
work resumed gainful employment after initiating 
treatment.  Patients who were asymptomatic at presen-
tation had better employment rates than those already 
suffering from HIV-associated illness. Many patients 
were employed in informal enterprises, and many of 
these patients were overwhelmed by new economic 
burdens levelled by their infection. Room remains for 
earlier diagnosis and for improved social services to 
mitigate the economic consequences of HIV infection. 
This may even enhance patients’ abilities to pay for 
expenses associated with medical treatment.  
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The benefit of HAART, and the unaddressed needs 
highlighted in our study population, merit considera-
tion by policy makers when making decisions about 




1. UNAIDS. AIDS Epidemic Update: December 
2007: UNAIDS and WHO; 19 November 2007 
2007. 978 92 9 173621 8. 
2. Bachmann MO, Booysen FL. Health and eco-
nomic impact of HIV/AIDS on South African 
households: a cohort study. BMC Public Health. 
Apr 1 2003;3:14. 
3. Bachmann MO, Booysen FL. Relationships be-
tween HIV/AIDS, income and expenditure over 
time in deprived South African households. AIDS 
Care. Oct 2004;16(7):817-826. 
4. Bachmann MO, Booysen FL. Economic causes 
and effects of AIDS in South African households. 
AIDS. Sep 11 2006;20(14):1861-1867. 
5. Chao LW, Pauly M, Szrek H, et al. Poor health 
kills small business: illness and microenterprises 
in South Africa. Health Aff (Millwood) Mar-Apr 
2007;26(2):474-482. 
6. Hosegood V, Preston-Whyte E, Busza J, Moitse S, 
Timaeus IM. Revealing the full extent of house-
holds' experiences of HIV and AIDS in rural 
South Africa. Soc Sci Med. Sep 2007;65(6):1249-
1259. 
7. Calmy A, Pinoges L, Szumilin E, et al. Generic 
fixed-dose combination antiretroviral treatment in 
resource-poor settings: multicentric observational 
cohort. AIDS. May 2006;20 (8):1163-1169. 
8. Hammond R, Harry TC. Efficacy of antiretroviral 
therapy in Africa: effect on immunological and vi-
rological outcome measures a meta-analysis. In-
ternational Journal of STD & AIDS May 
2008;19(5):291-296. 
9. Ivers LC, Kendrick D, Doucette K. Efficacy of 
antiretroviral therapy programs in resource-poor 
settings: A meta-analysis of the published litera-
ture. Clinical Infectious Diseases Jul 
2005;41(2):217-224. 
10. Laurent C, Kouanfack C, Koulla-Shiro S, et al. 
Effectiveness and safety of a generic fixed-dose 
combination of nevirapine, stavudine, and lami-
vudine in HIV-1-infected adults in Cameroon: 
open-label multicentre trial. Lancet. Jul 3-9 
2004;364(9428):29-34. 
11. Dray-Spira R, Lert F. Living and working with 
HIV in France in 2003: results from the ANRS-
EN12-VESPA Study. AIDS. Jan 2007;21 Suppl 
1:S29-36. 
12. Goldman DP, Bao Y. Effective HIV treatment and 
the employment of HIV(+) adults. Health Serv 
Res Dec 2004;39(6 Pt 1):1691-1712. 
13. Ajithkumar K, Iype T, Arun KJ, Ajitha BK, 
Aveenlal KP, Antony TP. Impact of antiretroviral 
therapy on vocational rehabilitation. AIDS Care 
Nov 2007;19(10):1310-1312. 
14. World Health Organization. WHO case defini-
tions of HIV for surveillance and revised clinical 
staging and immunological classification of HIV-
related disease in adults and children. Geneva; 
2007. 
15. Fogarty AS, Zablotska I, Rawstorne P, Prestage 
G, Kippax SC. Factors distinguishing employed 
from unemployed people in the Positive Health 
Study. AIDS Jan 2007;21 Suppl 1:S37-42. 
16. Bernell SL, Shinogle JA. The relationship be-
tween HAART use and employment for HIV-
positive individuals: an empirical analysis and 
policy outlook. Health Policy Feb 
2005;71(2):255-264. 
17. Alkenbrack Batteh SE, Forsythe S, Martin G, 
Chettra T. Confirming the impact of HIV/AIDS 
epidemics on household vulnerability in Asia: the 
case of Cambodia. AIDS Jul 2008;22 Suppl 
1:S103-111. 
18. Collins DL, Leibbrandt M. The financial impact 
of HIV/AIDS on poor households in South Africa 
AIDS Nov 2007;21 Suppl 7:S75-81. 
19. Mahal A, Canning D, Odumosu K, Okonkwo P. 
Assessing the economic impact of HIV/AIDS on 
Nigerian households: a propensity score matching 
approach. AIDS Jul 2008;22 Suppl 1:S95-101. 
20. Hart K. Informal Income Opportunities and Urban 
Employment in Ghana. The Journal of Modern 
African Studies 1973;11(1):61-89. 
21. Lyons M, Snoxell S. Sustainable urban liveli-
hoods and marketplace social capital: Crisis and 
strategy in petty trade. Urban Studies Jul 
2005;42(8):1301-1320. 
 
  
